@Article{ecn.2021.0472,
AUTHOR = {Yuancong Jiang, Deqiang Kong, Xiaolong Miao, Xing Yu, Zelai Wu, Han Liu, Weihua Gong},
TITLE = {Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease},
JOURNAL = {European Cytokine Network},
VOLUME = {32},
YEAR = {2021},
NUMBER = {4},
PAGES = {73--82},
URL = {http://www.techscience.com/ECN/v32n4/65055},
ISSN = {1952-4005},
ABSTRACT = {Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, with multifactorial
etiologies has led to a global health-associated burden in many countries. Substantial efforts are devoted to understand
the pathogenesis, behavioral and environmental triggers, which may be specifically valuable for the treatment of IBD.
The specific pathogenesis underlying IBD is as yet incompletely understood. The use of anti-cytokine therapy and small
molecule agents targeting the immune system is thought to restore the body’s intestinal barrier function and relieve
inflammation with manageable adverse effects. In this review, we report recent advances in anti-cytokine therapy and
treatment with small molecule agents for the management of IBD.},
DOI = {10.1684/ecn.2021.0472}
}